š§¬ Jacob Glanville - Centivax - Part 2 | Creating Bioinformatic Tools | Innovation vs. Organization in Biotech Companies | Finding Excitement in Your Work | Tech Transfer & āSeparation of Church and Stateā
In part 2 of the Biotech Startups Podcast episode, host Jon Chee dives deeper into his conversation with Jacob Glanville, Founder, CEO, & President of Centivax. Jake sheds light on his past experiences at Rinat Labs, a Pfizer company, and how he found a way to leverage his skills and experience to create new bioinformatic processes. Learn more about his initial idea for a universal vaccine and why he chose to pursue a PhD at Stanford.
Part 2 of 4.
My guest for this weekās episode is Jacob Glanville. Jacob is the Founder, CEO, & President of Centivax and was formerly the Co-founder, CEO, and President of Distributed Bio.
Join us as we sit down with Jake, discussing his time at Rinat Labs, a Pfizer company, and how he found a way to leverage his skills and experience to create new bioinformatic processes.
Learn more about his initial idea for a universal vaccine and why he chose to pursue a PhD at Stanford. Hear Jakeās view on how to be excited about what you do, and leveraging that excitement to pursue your goals, entrepreneurial or otherwise.
Please enjoy my conversation with Jake Glanville.
Find Our Guest, Jacob Glanville, at these links:
Find Our Host, Jon Chee, at these links:
Social & Website
Timestamps:
00:00 Intro
01:49 Episode start
03:42 Finding how to make yourself most useful
05:22 Why Big Pharma buys small biotechs
07:00 A lack of bioinformatic tools and solving for that issue
09:29 Collecting data on experiments and conducting meta-analysis
11:08 Analyzing antibody libraries and mice immunizations
12:14 Synthesizing the data to better understand antibodies and vaccination
14:09 Leaving Rinat/Pfizer, the idea of a universal vaccine
16:06 Getting a PhD and launching a company simultaneously
21:03 Starting Distributed Bio and navigating time at Stanford
25:29 Find out what makes you excited and pursue it
27:43 Tech transfer and keeping DB and Stanford work separate
30:08 Outro
Enriched Notes:
Topics Mentioned:
People Mentioned: